Gerresheimer and Corning joint venture to meet demand for Velocity Vials
Gerresheimer has established a joint venture with Corning to increase global access to the Velocity Vial technology platform, addressing the need for a high-quality and cost-effective injectable drug filling process.
The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s innovative Velocity Vial technology. Velocity Vials will be produced by the joint venture in existing Gerresheimer facilities for the international market, making the vials immediately available in North America, Europe, and Asia.
“As the leading solution provider for the pharma and biotech industry, Gerresheimer is dedicated to offering our customers best-in-class solutions to the industry’s toughest challenges,” said Dr. Lukas Burkhardt, Member of the Management Board of Gerresheimer AG. “By expanding our long-standing relationship with Corning, we add another integrated solution to deliver value for our customers. Our market-leading position in vials is further strengthened by this innovative vial technology.”
“Over the past two years, we’ve seen first-hand how vital Corning Velocity Vials have been to improving pharmaceutical-manufacturing performance and quality. Now, Corning is expanding access to Velocity Vials by partnering with Gerresheimer to co-manufacture and sell the product,” said Brendan Mosher, vice president and general manager of Corning Pharmaceutical Technologies. “The new model expands Velocity’s manufacturing footprint, localizes its supply chains, and gives customers the option to purchase directly from Corning or Gerresheimer. We are excited to welcome Gerresheimer as the first partner to join the Velocity Vial technology platform.”
